Scheme	O
of	O
the	O
activity	O
of	O
5	O
-	O
HT	O
(	O
A	O
)	O
and	O
norepinephrine	O
(	O
NE	O
)	O
(	O
B	O
)	O
neurotransmission	O
during	O
treatment	O
with	O
milnacipran	O
.	O

A	O
)	O
5	O
-	O
HT	O
system	O
.	O

Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
decreased	O
firing	O
of	O
5	B-Cell
-	I-Cell
HT	I-Cell
neurons	I-Cell
from	O
the	O
raphe	B-Tissue
nucleus	I-Tissue
possibly	O
due	O
in	O
part	O
to	O
increased	O
stimulation	O
of	O
somatodendritic	B-Cell
autoreceptors	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
full	O
recovery	O
in	O
the	O
firing	O
rate	O
of	O
5	B-Cell
-	I-Cell
HT	I-Cell
neurons	I-Cell
in	O
the	O
presence	O
of	O
milnacipran	O
thereby	O
leading	O
to	O
a	O
net	O
increase	O
in	O
5	O
-	O
HT	O
neurotransmission	O
.	O

Contributing	O
to	O
this	O
enhancement	O
are	O
:	O
1	O
)	O
the	O
normalized	O
firing	O
rate	O
of	O
5	B-Cell
-	I-Cell
HT	I-Cell
neurons	I-Cell
in	O
the	O
presence	O
of	O
milnacipran	O
2	O
)	O
the	O
desensitization	O
of	O
the	O
terminal	O
5	O
-	O
HT1B	O
autoreceptor	O
,	O
and	O
3	O
)	O
the	O
desensitization	O
of	O
the	O
alpha2	O
-	O
adrenergic	O
heteroreceptors	O
on	O
5	O
-	O
HT	O
terminals	O
.	O

B	O
)	O
NE	O
system	O
.	O

Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
increased	O
synaptic	B-Cellular_component
concentrations	O
of	O
NE	O
but	O
decreased	O
firing	O
of	O
the	O
NE	B-Cell
neurons	I-Cell
of	O
the	O
locus	B-Tissue
coeruleus	I-Tissue
due	O
to	O
increased	O
stimulation	O
of	O
the	O
somatodendritic	B-Cell
alpha2	O
-	O
adrenergic	O
autoreceptors	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
further	O
increase	O
in	O
synaptic	B-Cellular_component
concentrations	O
of	O
NE	O
due	O
to	O
desensitization	O
of	O
presynaptic	B-Cellular_component
autoreceptors	O
.	O

The	O
somatodendritic	B-Cell
alpha2	O
-	O
adrenergic	O
autoreceptors	O
do	O
not	O
desensitize	O
.	O

